Spots Global Cancer Trial Database for clear cell renal cell carcinoma
Every month we try and update this database with for clear cell renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab | NCT00866320 | Kidney Cancer | sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | NCT00176501 | Kidney Cancer | therapeutic all... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma | NCT05861778 | Clear Cell Rena... Suspected Recur... Recurrent Renal... | 89Zr-Girentuxim... | 18 Years - | Telix Pharmaceuticals (Innovations) Pty Limited | |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | NCT03284385 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | NCT06339138 | Chromophobe Ren... Clear Cell Papi... Clear Cell Rena... Kidney Oncocyto... Papillary Renal... Urothelial Carc... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer | NCT00278174 | Kidney Cancer | recombinant int... | 18 Years - | Case Comprehensive Cancer Center | |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | NCT05665361 | Advanced Clear ... Papillary Renal... | Sasanlimab Palbocicilib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | NCT00176501 | Kidney Cancer | therapeutic all... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | NCT00126503 | Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) | NCT06088134 | Clear Cell Rena... Prognostic Canc... Recurrent Renal... | - | First Affiliated Hospital of Chongqing Medical University | ||
| Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | NCT01684397 | Clear Cell Rena... Stage IV Renal ... | Bevacizumab Laboratory Biom... Pazopanib Hydro... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | NCT00087022 | Kidney Cancer | girentuximab placebo | 18 Years - 120 Years | Heidelberg Pharma AG | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | NCT02496208 | Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | NCT03473730 | Bladder Urothel... Clear Cell Rena... Malignant Urina... Metastatic Kidn... Stage IV Renal ... | Biopsy Daratumumab Laboratory Biom... Metastasectomy Nephrectomy | 18 Years - | M.D. Anderson Cancer Center | |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | NCT03793166 | Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ... | Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | NCT01791387 | Clear Cell Rena... | Dovitinib | 18 Years - | Auckland District Health Board | |
| Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | NCT00087022 | Kidney Cancer | girentuximab placebo | 18 Years - 120 Years | Heidelberg Pharma AG | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | NCT01582009 | Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ... | panobinostat everolimus laboratory biom... pharmacological... liquid chromato... mass spectromet... enzyme-linked i... immunohistochem... | 18 Years - | Roswell Park Cancer Institute | |
| Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | NCT04370509 | Metastatic Clea... Recurrent Clear... Stage III Renal... Stage IV Renal ... Clear Cell Rena... | Axitinib (VEGF-... Cytoreductive N... Metastasectomy ... Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT00727532 | Hereditary Clea... Kidney Cancer | Sorafenib | 18 Years - 120 Years | Northwestern University | |
| PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma | NCT03108066 | VHL Gene Mutati... VHL VHL Syndrome VHL Gene Inacti... Von Hippel Von Hippel-Lind... Von Hippel's Di... Von Hippel-Lind... Clear Cell Rena... Clear Cell RCC ccRCC | PT2385 Tablets | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03015740 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | NCT02607553 | Clear Cell Rena... | G-202 | 18 Years - | GenSpera, Inc. | |
| A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors | NCT05536141 | Clear Cell Rena... Solid Tumors | AB521 | 18 Years - | Arcus Biosciences, Inc. | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | NCT01164228 | Kidney Cancer | Gemcitabine Sunitinib | 18 Years - | Eastern Cooperative Oncology Group | |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | NCT05199272 | Solid Tumor Clear Cell Rena... Epithelial Ovar... Fallopian Tube ... Primary Periton... Neuroendocrine ... MSI-H Cancer Cancer With A H... Extensive-stage... | 23ME-00610 | 12 Years - | 23andMe, Inc. | |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | NCT04810078 | Clear Cell Rena... | Nivolumab and r... Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | NCT02575222 | Clear Cell Rena... | Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | NCT03149159 | Clear Cell Rena... Metastatic Rena... | Nivolumab Ipilimumab Steriotactic ra... | 18 Years - | Medical University of South Carolina | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer | NCT00100906 | Kidney Cancer | IL-2 ATRA | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | NCT01649180 | Renal Cell Carc... | Axitinib | 18 Years - | PrECOG, LLC. | |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | NCT02496208 | Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | NCT00293501 | Kidney Cancer | tinzaparin sodi... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | NCT01243359 | Clear Cell Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... Unspecified Adu... | sunitinib malat... bevacizumab pharmacological... laboratory biom... fluorine F 18 f... positron emissi... computed tomogr... | 18 Years - | National Cancer Institute (NCI) | |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | NCT01599832 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | pazopanib hydro... laboratory biom... dynamic contras... pharmacogenomic... | 18 Years - | University of Chicago | |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | NCT01038778 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Aldesleukin Computed Tomogr... Entinostat Fludeoxyglucose... Laboratory Biom... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | NCT03682289 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast... | Ceralasertib Olaparib Durvalumab | 18 Years - | University of California, San Francisco | |
| Investigating Patient Satisfaction With Oral Anti-Cancer Treatment | NCT02247583 | Clear Cell Rena... | 18 Years - | KU Leuven | ||
| RPI.4610 in Treating Patients With Metastatic Kidney Cancer | NCT00021021 | Kidney Cancer | anti-FLT-1 ribo... | 18 Years - | National Cancer Institute (NCI) | |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | NCT01835158 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Cabozantinib S-... Laboratory Biom... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | NCT04022343 | Clear Cell Rena... Renal Cell Carc... Stage III Renal... | Cabozantinib | 18 Years - | Emory University | |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | NCT00480389 | Renal Cell Carc... Metastatic Dise... | Sorafenib | 18 Years - | University Health Network, Toronto | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | NCT00326898 | Clear Cell Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... | Laboratory Biom... Placebo Quality-of-Life... Sorafenib Tosyl... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer | NCT00093405 | Kidney Cancer | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | NCT00126594 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | Sorafenib Tosyl... Recombinant Int... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer | NCT04958473 | Renal Cell Carc... Clear Cell Rena... | Sintilimab Axitinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | NCT02307474 | Clear Cell Rena... Renal Cell Carc... | Stereotactic Ra... Pazopanib Hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | NCT00401128 | Kidney Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | The Cleveland Clinic | |
| Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) | NCT01069770 | Clear Cell Rena... Metastasis | Sunitinib | 18 Years - | Korean Urological Oncology Society | |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | NCT02595918 | Clear Cell Rena... Metastatic Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... | Metastasectomy Nephrectomy Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | NCT00301990 | Kidney Cancer | aldesleukin bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00589550 | Kidney Cancer | PEG-interferon ... Sorafenib gene expression... polymerase chai... reverse transcr... flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | NCT00126659 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | therapeutic con... sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | NCT02923531 | Clear Cell Rena... | X4P-001 Nivolumab | 18 Years - | X4 Pharmaceuticals | |
| A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma | NCT05728515 | Clear Cell Rena... | 68Ga-NY104 | 18 Years - | Peking Union Medical College Hospital | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | NCT00331409 | Kidney Cancer | Everolimus imatinib mesyla... | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | NCT00112840 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | CCI-779 Bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | NCT02885649 | Clear Cell Rena... Stage I Renal C... | Enzalutamide Laboratory Biom... Nephrectomy | 18 Years - | Rutgers, The State University of New Jersey | |
| Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | NCT00293501 | Kidney Cancer | tinzaparin sodi... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00589550 | Kidney Cancer | PEG-interferon ... Sorafenib gene expression... polymerase chai... reverse transcr... flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | NCT00853125 | Kidney Cancer | therapeutic all... sunitinib malat... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | NCT00303862 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
